Please assess the completion status of the following clinical trial:

Trial Title: Crossover Study of Neuropsychological Effects of Lacosamide and Carbamazepine Immediate Release in Healthy Subjects

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: CROSSOVER
- Observational Model: None
- Primary Purpose: None
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE1
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Subjects are between 18 and 55 years of age (inclusive)~* Subjects have a Body Mass Index (BMI) between 18 and 35 kg/m\^2 (inclusive)~* Subjects must be in generally good health with no clinically relevant health conditions~Exclusion Criteria:~* Subject has previously been randomized in this study or subject has received LCM or CBZ~* Subjects may not currently be participating in or have participated in the past 30 days in a clinical drug or device study~* Subjects may not have a history of drug or alcohol abuse within the last 2 years~* Subjects may not consume more than 40 g of alcohol per day~* Females who are pregnant or nursing are ineligible; females of childbearing potential must agree to adhere to protocol conception guidelines~* Subjects may not score ≤ 70 on the Peabody Picture Vocabulary Test (PPVT)~* Subjects with a lifetime history of suicide attempt or suicidal ideation in the past 6 months may not participate~* Subjects with a diet that deviates notably from the normal amounts of protein, carbohydrate, and fat, as judged by the investigator are ineligible to participate~* Subjects may not consume more than 600 mg of caffeine/day~* Subjects may not smoke more than 10 cigarettes per day or have done so within 6 months prior to Screening~* Subjects may not have a positive alcohol breath test or urine drug screen at Screening

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 55 Years
- Healthy Volunteers: t

Study Arms:
- LCM 300 mg/CBZ-IR 600 mg (Type: OTHER): Crossover sequence of experimental treatment and active comparator
- CBZ-IR 600 mg/LCM 300 mg (Type: OTHER): Crossover sequence of active comparator and experimental treatment

Based on this trial design, predict the completion outcome and termination type (if applicable).